Loading...
Market
Outcome of Xaira's first clinical trial by 2026
4
Resolution / Starting Odds
Highly successful • 25%
Partially successful • 25%
Inconclusive results • 25%
Failed • 25%
Clinical trial results published on clinicaltrials.gov or similar platforms
Story
Xaira, Led by CEO Marc Tessier-Lavigne, Raises $1B for RFdiffusion Tech
Apr 25, 2024, 12:25 AM
Xaira, a new biotechnology company, has successfully raised over $1 billion in committed capital, marking one of the largest funding rounds in biotech history. The company, led by CEO Marc Tessier-Lavigne, is set to focus on next-generation technology in biopharma, leveraging AI and RFdiffusion from David Baker's lab. The funding round saw participation from major venture capital firms including Arch, Foresite, F-Prime, NEA, Sequoia, Lux, Lightspeed, and Two Sigma. This significant financial backing underscores the growing interest and investment in tech-driven biopharma solutions.
View original story
Similar markets
Successful • 33%
Mixed results • 34%
Unsuccessful • 33%
Highly successful • 33%
Moderately successful • 34%
Unsuccessful • 33%
Does not progress past Phase 1 • 25%
Completes Phase 1 but not Phase 2 • 25%
Completes Phase 2 but not Phase 3 • 25%
Advances to Phase 3 or beyond • 25%
Improved patient outcomes • 33%
Mixed or unchanged outcomes • 33%
Negative outcomes or side effects • 34%
Successful with no major side effects • 33%
Successful with manageable side effects • 33%
Unsuccessful due to efficacy or safety issues • 34%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
Not in clinical trials • 20%
Phase 1 • 20%
Phase 2 • 20%
Phase 3 • 20%
Approved for use • 20%